Ocular Toxicity News Today

Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treat

TIVDAK is the first antibody-drug conjugate to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from...

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Apr 29, 2024--

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Validation is supported by data from Phase 3 innovaTV 301 trial ...

Medical professionals explore CSCC and BCC treatment in high-risk, immunocompromised patients—specifically in the setting of organ transplantation.

Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.

Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.

The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC.